Search results
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoWe expect investors to focus on the sales performance of Novavax, Inc.’s NVAX protein-based COVID-19...
Novavax (NVAX) COVID Jab Receives EU Nod for Adolescents
Zacks via Yahoo Finance· 2 years agoNovavax NVAX recently announced that the European Commission (“EC”) expanded its conditional...
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
Zacks via Yahoo Finance· 2 years agoDrug approvals and other regulatory news are in focus in the biotech sector. Updates on booster...
Novavax's (NVAX) COVID Jab Gets Full Approval in Europe
Zacks via Yahoo Finance· 10 months agoNovavax NVAX announced that the European Commission had granted full marketing authorization for its...
Novavax Prototype COVID-19 Vaccine Data Shows Benefit Against Variants
Benzinga via Yahoo Finance· 2 years agoNovavax Inc (NASDAQ: NVAX) presented data from the Phase 3 PREVENT-19 trial and Study 307 (Lot...
Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More
Zacks via Yahoo Finance· 1 year agoThe biotech sector was in focus with key pipeline and regulatory updates. Among these, Geron...
Better Buy: Novavax or BioNTech Stock?
Motley Fool· 1 year agoLast week, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the Food and Drug Administration (FDA) recommended a move toward a...
Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More
Zacks via Yahoo Finance· 2 years agoDrug approvals and other regulatory updates are in focus in the biotech sector. COVID-19 vaccine...
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
Zacks via Yahoo Finance· 2 years agoIt was a busy week for the volatile biotech sector, with important regulatory and pipeline updates...
Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half
Zacks via Yahoo Finance· 2 years agoNovavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market...